MGMT methylation assessment in glioblastoma: MS-MLPA versus human methylation 450K beadchip array and immunohistochemistry

详细信息    查看全文

• 作者：S. Trabelsi ; N. Mama ; M. Ladib ; N. Karmeni…
• 关键词：Methylation ; MGMT ; MS ; MLPA ; HM450 K beadchip array
• 刊名：Clinical and Translational Oncology
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：18
• 期：4
• 页码：391-397
• 全文大小：955 KB
• 参考文献：1.Pegg AE. Repair of O(6)-alkylguanine by alkyltransferases. Mutat Res. 2000;462(2–3):83–100.CrossRef PubMed
  2.Karran P, Bignami M. DNA damage tolerance, mismatch repair and genome instability. BioEssays. 1994;16(11):833–9.CrossRef PubMed
  3.Herfarth KK, Brent TP, Danam RP, Remack JS, Kodner IJ, Wells SA Jr, et al. A specific CpG methylation pattern of the MGMT promoter region associated with reduced MGMT expression in primary colorectal cancers. Mol Carcinog. 1999;24(2):90–8.CrossRef PubMed
  4.Ogino S, Meyerhardt JA, Kawasaki T, Clark JW, Ryan DP, Kulke MH, et al. CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Virchows Arch. 2007;450(5):529–37.CrossRef PubMed
  5.Wolf P, Hu YC, Doffek K, Sidransky D, Ahrendt SA. O(6)-Methylguanine-DNA methyltransferase promoter hypermethylation shifts the p53 mutational spectrum in non-small cell lung cancer. Cancer Res. 2001;61(22):8113–7.PubMed
  6.Wu X, Wilson TE, Lieber MR. A role for FEN-1 in nonhomologous DNA end joining: the order of strand annealing and nucleolytic processing events. Proc Natl Acad Sci USA. 1999;96(4):1303–8.CrossRef PubMed PubMedCentral
  7.Oue N, Shigeishi H, Kuniyasu H, Yokozaki H, Kuraoka K, Ito R, et al. Promoter hypermethylation of MGMT is associated with protein loss in gastric carcinoma. Int J Cancer. 2001;93(6):805–9.CrossRef PubMed
  8.Goldenberg D, Harden S, Masayesva BG, Ha P, Benoit N, Westra WH, et al. Intraoperative molecular margin analysis in head and neck cancer. Arch Otolaryngol Head Neck Surg. 2004;130(1):39–44.CrossRef PubMed
  9.Maruya S, Issa JP, Weber RS, Rosenthal DI, Haviland JC, Lotan R, et al. Differential methylation status of tumor-associated genes in head and neck squamous carcinoma: incidence and potential implications. Clin Cancer Res. 2004;10(11):3825–30.CrossRef PubMed
  10.Steinmann K, Sandner A, Schagdarsurengin U, Dammann RH. Frequent promoter hypermethylation of tumor-related genes in head and neck squamous cell carcinoma. Oncol Rep. 2009;22(6):1519–26.PubMed
  11.Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000;343(19):1350–4.CrossRef PubMed
  12.Mellai M, Caldera V, Annovazzi L, Chio A, Lanotte M, Cassoni P, et al. MGMT promoter hypermethylation in a series of 104 glioblastomas. Cancer Genom Proteom. 2009;6(4):219–27.
  13.Shamsara J, Sharif S, Afsharnezhad S, Lotfi M, Raziee HR, Ghaffarzadegan K, et al. Association between MGMT promoter hypermethylation and p53 mutation in glioblastoma. Cancer Invest. 2009;27(8):825–9.CrossRef PubMed
  14.Lahtz C, Pfeifer GP. Epigenetic changes of DNA repair genes in cancer. J Mol Cell Biol. 2011;3(1):51–8.CrossRef PubMed PubMedCentral
  15.Bady P, Sciuscio D, Diserens AC, Bloch J, van den Bent MJ, Marosi C, et al. MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathol. 2012;124(4):547–60.CrossRef PubMed PubMedCentral
  16.Lee JY, Park CK, Park SH, Wang KC, Cho BK, Kim SK. MGMT promoter gene methylation in pediatric glioblastoma: analysis using MS-MLPA. Childs Nerv Syst. 2011;27(11):1877–83.CrossRef PubMed
  17.Park CK, Kim J, Yim SY, Lee AR, Han JH, Kim CY, et al. Usefulness of MS-MLPA for detection of MGMT promoter methylation in the evaluation of pseudoprogression in glioblastoma patients. Neuro Oncol. 2010;13(2):195–202.CrossRef PubMed PubMedCentral
  18.Jeuken JW, Cornelissen SJ, Vriezen M, Dekkers MM, Errami A, Sijben A, et al. MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. Lab Invest. 2007;87(10):1055–65.CrossRef PubMed
  19.Chakravarti A, Erkkinen MG, Nestler U, Stupp R, Mehta M, Aldape K, et al. Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. Clin Cancer Res. 2006;12(15):4738–46.CrossRef PubMed
  20.van den Bent MJ, Dubbink HJ, Sanson M, van der Lee-Haarloo CR, Hegi M, Jeuken JW, et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J Clin Oncol. 2009;27(35):5881–6.CrossRef PubMed PubMedCentral
  21.van den Bent MJ, Erdem-Eraslan L, Idbaih A, de Rooi J, Eilers PH, Spliet WG, et al. MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clin Cancer Res. 2009;19(19):5513–22.CrossRef
  22.Burke E, Grobler M, Elderfield K, Bond F, Crocker M, Taylor R, et al. Double-labelling immunohistochemistry for MGMT and a “cocktail” of non-tumourous elements is a reliable, quick and easy technique for inferring methylation status in glioblastomas and other primary brain tumours. Acta Neuropathol Commun. 2013;1:22.CrossRef PubMed PubMedCentral
  
• 作者单位：S. Trabelsi (1)
  N. Mama (2)
  M. Ladib (3)
  N. Karmeni (3)
  M. Haddaji Mastouri (1)
  M. Chourabi (1)
  M. Mokni (4)
  K. Tlili (2)
  H. Krifa (3)
  M. T. Yacoubi (4)
  A. Saad (1)
  D. H’mida Ben Brahim (1)
  
  1. Laboratory of Cytogenetics, Molecular Genetics and Reproductive Biology, Farhat Hached University Hospital, Street Ibn Eljazzar, 4000, Sousse, Tunisia
  2. Department of Imagery, Sahloul University Hospital, Sousse, Tunisia
  3. Department of Neurosurgery, Sahloul University Hospital, Sousse, Tunisia
  4. Department of Cytopathology, Farhat Hached University Hospital, Sousse, Tunisia
  
• 刊物主题：Oncology;
• 出版者：Springer Milan
• ISSN：1699-3055

文摘

Purpose The MGMT gene encodes a DNA repair enzyme that counteracts with chemotherapy efficiency, specifically with alkylating agents such as temozolomide (TMZ). It is well established that MGMT methylation should be screened as a predictive marker for TMZ in glioblastoma, and we thus aimed to determine a reliable and practical diagnostic method of MGMT methylation detection.